C10orf82 Inhibitors act through a variety of mechanisms to decrease the activity of the protein C10orf82 by targeting specific pathways and functions that are presumed to be related to its activity. One mechanism is the inhibition of protein kinases that are responsible for the phosphorylation of proteins; given C10orf82 requires phosphorylation for its function, kinase inhibitors would lead to a decrease in its activity. This can occur through direct inhibition of kinases that act on C10orf82 or by targeting upstream regulators that control its phosphorylation status. Similarly, compounds that inhibit the PI3K/AKT or MAPK pathways can prevent the necessary post-translational modifications or signaling events needed for C10orf82 to function, assuming it is a downstream effector in these pathways. For instance, if C10orf82 activity is upregulated by AKT, PI3K inhibitors would reduce C10orf82 activity by decreasing AKT signaling.
Additionally, mTOR plays a pivotal role in cell growth and proliferation, and inhibitors ofC10orf82 Inhibitors act through a variety of mechanisms to decrease the activity of the protein C10orf82 by targeting specific pathways and functions that are presumed to be related to its activity. One mechanism is the inhibition of protein kinases that are responsible for the phosphorylation of proteins; assuming C10orf82 requires phosphorylation for its function, kinase inhibitors would lead to a decrease in its activity. This can occur through direct inhibition of kinases that act on C10orf82 or by targeting upstream regulators that control its phosphorylation status. Similarly, compounds that inhibit the PI3K/AKT or MAPK pathways can prevent the necessary post-translational modifications or signaling events needed for C10orf82 to function, assuming it is a downstream effector in these pathways. For instance, since C10orf82 activity is upregulated by AKT, PI3K inhibitors would reduce C10orf82 activity by decreasing AKT signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting key kinases that phosphorylate C10orf82, staurosporine may reduce its functional activity given C10orf82 relies on phosphorylation for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling can regulate a multitude of cellular processes. Inhibition of PI3K could decrease downstream AKT activation, which, given C10orf82 function is AKT-dependent, would lead to decreased functionality of C10orf82. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK pathway. Given C10orf82 is regulated by MAPK signaling, inhibiting MEK would lead to reduced activity of C10orf82. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is central to cell growth and proliferation. Given C10orf82 is involved in these processes, mTOR inhibition could reduce C10orf82 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. Given C10orf82 is degraded by the proteasome, bortezomib could increase levels of the protein, but it could also disrupt functional protein folding, leading to inhibition of C10orf82 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Given C10orf82 activity is contingent on p38 MAPK signaling, then inhibition by SB203580 would diminish C10orf82 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. It would reduce C10orf82 activity by inhibiting the PI3K/AKT pathway if C10orf82 function is reliant on this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family. Given C10orf82 operates downstream of JNK, its activity would be decreased by SP600125. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. Given C10orf82 is involved in cell cycle regulation where Aurora kinases play a role, inhibition could diminish C10orf82 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor. Given C10orf82 is involved in EGFR signaling pathways, its activity could be inhibited by blocking EGFR with gefitinib. | ||||||